Search

Your search keyword '"Stockler, Martin R."' showing total 758 results
Start Over Author "Stockler, Martin R."
758 results on '"Stockler, Martin R."'

2. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Author

Tan, Lavinia, Brown, Chris, Mersiades, Antony, Lee, Chee Khoon, John, Thomas, Kao, Steven, Newnham, Genni, O’Byrne, Kenneth, Parakh, Sagun, Bray, Victoria, Jasas, Kevin, Yip, Sonia, Wong, Stephen Q., Ftouni, Sarah, Guinto, Jerick, Chandrashekar, Sushma, Clarke, Stephen, Pavlakis, Nick, Stockler, Martin R., Dawson, Sarah-Jane, and Solomon, Benjamin J.

Published
2024
Full Text
View/download PDF

4. Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance

Author

Sharifi, Nima, Diaz, Robert, Lin, Hui-Ming, Roberts, Evan, Horvath, Lisa G., Martin, Andrew, Stockler, Martin R., Yip, Sonia, Subhash, Vinod V., Portman, Neil, Davis, Ian D., and Sweeney, Christopher J.

Subjects
Medical research, Medicine, Experimental, Prostate cancer -- Physiological aspects -- Prognosis, Metastasis -- Physiological aspects, Men -- Health aspects, Hormones -- Health aspects, Epigenetic inheritance -- Health aspects
Abstract

BACKGROUND. Metastatic hormone-sensitive prostate cancer (mHSPC) is androgen dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal testosterone suppression. Since 2014, overall survival (OS) has been prolonged with addition of other systemic therapies, such as adrenal androgen synthesis blockers, potent androgen receptor blockers, or docetaxel, to ADT. HSD3B1 encodes the rate-limiting enzyme for nongonadal androgen synthesis, 3[beta]-hydroxysteroid dehydrogenase-1, and has a common adrenal-permissive missense-encoding variant that confers increased synthesis of potent androgens from nongonadal precursor steroids and poorer prostate cancer outcomes. METHODS. Our prespecified hypothesis was that poor outcome associated with inheritance of the adrenal-permissive HSD3B1 allele with ADT alone is reversed in patients with low-volume (LV) mHSPC with up-front ADT plus addition of androgen receptor (AR) antagonists to inhibit the effect of adrenal androgens. HSD3B1 genotype was obtained in 287 patients with LV disease treated with ADT + AR antagonist only in the phase III Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET) trial and was associated with clinical outcomes. RESULTS. Patients who inherited the adrenal-permissive HSD3B1 allele had more favorable 5-year clinical progression-free survival and OS when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen compared with their counterparts who did not have adrenal-permissive HSD3B1 inheritance. HSD3B1 was also associated with OS after accounting for known clinical variables. Patients with both genotypes benefited from early enzalutamide. CONCLUSION. These data demonstrated an inherited physiologic driver of prostate cancer mortality is associated with clinical outcomes and is potentially pharmacologically reversible. FUNDING. National Cancer Institute, NIH; Department of Defense; Prostate Cancer Foundation, Australian National Health and Medical Research Council., Introduction Prostate cancer has long been recognized to be an androgen-dependent disease, with some cancers being more dependent than others. Androgen deprivation therapy (ADT) with gonadal testosterone suppression has therefore [...]

Published
2024
Full Text
View/download PDF

6. Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report

Author

Meade, Angela, Frangou, Elena, Choodari-Oskooei, Babak, Larkin, James, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Gedye, Craig, Harrison, David J., Kaplan, Rick, Mulhere, Salena, Nathan, Paul, Patel, Grisma, Patel, Jay, Plant, Hannah, Ritchie, Alastair, Rush, Hannah, Shakeshaft, Clare, Stockler, Martin R., Suarez, Cristina, Thompson, Jemima, Thorogood, Nat, Venugopal, Balaji, and Parmar, Mahesh K.B.

Published
2024
Full Text
View/download PDF

7. Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

Author

Roncolato, Felicia, King, Madeleine T., O'Connell, Rachel L., Lee, Yeh Chen, Joly, Florence, Hilpert, Felix, Lanceley, Anne, Yoshida, Yoshio, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Ledermann, Jonathan A., Berton, Dominique, Sehouli, Jalid, Kaminsky, Marie-Christine, Stockler, Martin R., and Friedlander, Michael

Published
2024
Full Text
View/download PDF

11. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Author

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, and Davis, Ian D

Published
2024
Full Text
View/download PDF

12. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Bailey, Dale, Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Crumbaker, Megan, Dhiantravan, Nattakorn, Hamid, Anis, Haskali, Mohammad, Hung, Terry, Kong, Grace, Lawrence, Nick, Lewin, Jeremy, McCarthy, Michael, Moodie, Kate, Murphy, Declan, Nguyen, Andrew, Pook, David, Ravi Kumar, Aravind, Roach, Paul, Roselt, Peter, Saghebi, Javad, Schembri, Geoff, Spain, Lavinia, Subramaniam, Shalini, Thang, Sue Ping, Thomas, Paul, Tran, Ben, Wallace, Roslyn, Yip, Sonia, Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, and Davis, Ian D

Published
2024
Full Text
View/download PDF

13. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial

Author

Mileshkin, Linda R, Moore, Kathleen N, Barnes, Elizabeth H, Gebski, Val, Narayan, Kailash, King, Madeleine T, Bradshaw, Nathan, Lee, Yeh Chen, Diamante, Katrina, Fyles, Anthony W, Small, William, Jr, Gaffney, David K, Khaw, Pearly, Brooks, Susan, Thompson, J Spencer, Huh, Warner K, Mathews, Cara A, Buck, Martin, Suder, Aneta, Lad, Thomas E, Barani, Igor J, Holschneider, Christine H, Van Dyk, Sylvia, Quinn, Michael, Rischin, Danny, Monk, Bradley J, and Stockler, Martin R

Published
2023
Full Text
View/download PDF

14. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Author

Abdi, Ehtesham, Allan, Suzanne, Bastick, Patricia, Begbie, Stephen, Blum, Robert, Briscoe, Karen, Brungs, Daniel, Bydder, Sean, Chittajallu, Bala Renuka, Cronk, Michelle, Cuff, Katharine, Davis, Ian D, Dowling, Anthony, Frydenberg, Mark, George, Matthew, Horvath, Lisa, Hovey, Elizabeth, Joshua, Anthony, Karanth, Narayan, Kichenadasse, Ganessan, Krieger, Laurence, Marx, Gavin, Mathlum, Maitham, Nott, Louise, Otty, Zulfiquer, Parnis, Francis, Pook, David, Sandhu, Shahneen, Sewak, Sanjeev, Stevanovic, Amanda, Stockler, Martin, Suder, Aneta, Tan, Hsiang, Torres, Javier, Troon, Simon, Underhill, Craig, Weickhardt, Andrew, Zielinski, Robert, Abbas, Tahir, Anan, Ghadeer, Booth, Chris, Campbell, Holly, Chi, Kim, Chin, Joseph, Chouinard, Edmond, Donnelly, Bryan, Drachenberg, Darrel, Faghih, Amir, Finelli, Antonio, Hotte, Sebastien, Noonan, Krista, North, Scott, Rassouli, Mohammad, Reaume, Neil, Rendon, Ricardo, Saad, Fred, Sadikov, Evgeny, Vigneault, Eric, Zalewski, Pawel, McCaffrey, John, McDermott, Ray, Morris, Patrick, O'Connor, Miriam, Donnellan, Paul, O'Donnell, Dearbhaile, Edwards, Jim, Fong, Peter, Tan, Alvin, Chowdhury, Simon, Crabb, Simon, Khan, Omar, Khoo, Vincent, Macdonald, Graham, Payne, Heather, Robinson, Angus, Shamash, Jonathon, Staffurth, John, Thomas, Carys, Thomson, Alastair, Sweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Cheung, Leanna, Chi, Kim N, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, McJannett, Margaret, North, Scott A, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Thean Hsiang, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y, and Zielinski, Robert R

Published
2023
Full Text
View/download PDF

17. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Author

Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, and Zhang, Alison Y

Published
2022
Full Text
View/download PDF

18. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Author

Mak, Blossom, Lin, Hui-Ming, Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Zhang, Alison, Crumbaker, Megan, Tan, Winston, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Hoy, Andrew J., Du, Pan, Yu, Jianjun, Jia, Shidong, Joshua, Anthony M., Waugh, David J., Butler, Lisa M., Kohli, Manish, Meikle, Peter J., Azad, Arun A., and Horvath, Lisa G.

Published
2022
Full Text
View/download PDF

19. Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

Author

Gafita, Andrei, primary, Martin, Andrew J., additional, Emmett, Louise, additional, Eiber, Matthias, additional, Iravani, Amir, additional, Fendler, Wolfgang P., additional, Buteau, James, additional, Sandhu, Shahneen, additional, Azad, Arun A., additional, Herrmann, Ken, additional, Stockler, Martin R., additional, Davis, Ian D., additional, and Hofman, Michael S., additional

Published
2024
Full Text
View/download PDF

20. Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer

Author

Mahon, Kate L., primary, Sutherland, Sarah IM, additional, Lin, Hui Ming, additional, Stockler, Martin R., additional, Gurney, Howard, additional, Mallesara, Girish, additional, Briscoe, Karen, additional, Marx, Gavin, additional, Higano, Celestia S., additional, de Bono, Johann S., additional, Chi, Kim N., additional, Clark, Georgina, additional, Breit, Samuel N., additional, Brown, David A., additional, and Horvath, Lisa G., additional

Published
2024
Full Text
View/download PDF

21. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

Author

Lin, Hui-Ming, Mak, Blossom, Yeung, Nicole, Huynh, Kevin, Meikle, Thomas G., Mellett, Natalie A., Kwan, Edmond M., Fettke, Heidi, Tran, Ben, Davis, Ian D., Mahon, Kate L., Zhang, Alison, Stockler, Martin R., Briscoe, Karen, Marx, Gavin, Crumbaker, Megan, Stricker, Phillip D., Du, Pan, Yu, Jianjun, Jia, Shidong, Scheinberg, Tahlia, Fitzpatrick, Michael, Bonnitcha, Paul, Sullivan, David R., Joshua, Anthony M., Azad, Arun A., Butler, Lisa M., Meikle, Peter J., and Horvath, Lisa G.

Published
2021
Full Text
View/download PDF

23. The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research

Author

Ranganathan, Priya, Chinnaswamy, Girish, Sengar, Manju, Gadgil, Durga, Thiagarajan, Shivakumar, Bhargava, Balram, Booth, Christopher M, Buyse, Marc, Chopra, Sanjiv, Frampton, Chris, Gopal, Satish, Grant, Nick, Krailo, Mark, Langley, Ruth, Mathur, Prashant, Paoletti, Xavier, Parmar, Mahesh, Purushotham, Arnie, Pyle, Douglas, Rajaraman, Preetha, Stockler, Martin R, Sullivan, Richard, Swaminathan, Soumya, Tannock, Ian, Trimble, Edward, Badwe, Rajendra A, and Pramesh, C S

Published
2021
Full Text
View/download PDF

24. Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy

Author

Cohen, Paul A., Leung, Yee, Anderson, Lyndal, van der Griend, Rachael, Chivers, Paola, Bilic, Sanela, Bittinger, Sophie, Brand, Alison, Bulsara, Max K., Codde, Jim, Eva, Lois, Farrell, Louise, Harker, Dianne, Herbst, Unine, Jeffares, Stephanie, Loh, Diane, McNally, Orla, Mohan, Ganendra Raj, Nicholson, Tarryn, Powell, Aime, Salfinger, Stuart G., Simcock, Bryony, Stewart, Colin, Silvers, Julie, Stockler, Martin R., Sykes, Peter, Stoyles, Pennie, Tan, Adeline, Tan, Ai Ling, and Wrede, C. David H.

Published
2020
Full Text
View/download PDF

25. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials.

Author

Naher, Sayeda K., Mercieca-Bebber, Rebecca, Siu, Derrick, Stockler, Martin R., Kiely, Belinda E., and Grimison, Peter

Subjects
OVERALL survival, PERCENTILES, IMMUNOTHERAPY, ADENOCARCINOMA, DECISION making
Abstract

We aimed to summarize survival data from RCTs in patients with GO adenocarcinoma; estimate and explain worst-, typical-, and best-case-scenarios of survival time; and determine if simple multiples of median overall survival (mOS) could estimate these percentiles. We systematically searched RCTs of systemic therapies for GO adenocarcinoma published 2000–2022. The following key percentiles were extracted from overall survival curves: 90th (worst-case), 75th (lower-typical), 25th (upper-typical), and 10th (best-case). We tested if these percentiles could be estimated by simple multiples of mOS: 0.25 of the median for the 90th percentile, 0.5 for the 75th, 2 for the 25th, and 3 for the 10th. We identified 44 trials (22,447 participants). For first line chemotherapy and immunotherapy combined (CI) trials (n = 3) worst-to-best case survival time ranged from 4 months to not reached, compared to 3–30 months for other trials (n = 27) and 1–23 months for subsequent lines (n = 14). Simple multiples of mOS accurately estimated the following survival percentiles: 90th (n = 3/3 trials), 75th (n = 3/3), and 25th (n = 2/3) in first line CI trials. In other first line trials, the mOS accurately estimated the 90th survival percentile in n = 22/27 trials, 75th percentile in n = 26/27, 25th percentile in 27/27 trials, and 10th percentile in 22/27 trials. Simple multiples of the mOS accurately predicted the 90th, 75th, 25th, and 10th survival percentiles in the majority of trials of second and subsequent lines apart from chemotherapy and immunotherapy only trials. We provide realistic, evidence-based prognostic information as scenarios for survival time which can inform clinical decision-making. Simple multiples of the mOS accurately estimated the percentiles for most groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Author

Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia, and Stockler, Martin R

Published
2020
Full Text
View/download PDF

28. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Author

Lee, Yeh Chen, King, Madeleine T, OʼConnell, Rachel L, Lanceley, Anne, Joly, Florence, Hilpert, Felix, Davis, Alison, Roncolato, Felicia T, Okamoto, Aikou, Bryce, Jane, Donnellan, Paul, Oza, Amit M, Avall-Lundqvist, Elisabeth, Berek, Jonathan S, Ledermann, Jonathan A, Berton, Dominique, Sehouli, Jalid, Feeney, Amanda, Kaminsky, Marie-Christine, Diamante, Katrina, Stockler, Martin R, and Friedlander, Michael L

Published
2022
Full Text
View/download PDF

34. Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

Author

Stockler, Martin R, Hilpert, Felix, Friedlander, Michael, King, Madeleine T, Wenzel, Lari, Lee, Chee Khoon, Joly, Florence, de Gregorio, Nikolaus, Arranz, José Angel, Mirza, Mansoor Raza, Sorio, Roberto, Freudensprung, Ulrich, Sneller, Vesna, Hales, Gill, and Pujade-Lauraine, Eric

Subjects
Cancer, Rare Diseases, Ovarian Cancer, Clinical Research, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Doxorubicin, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Organoplatinum Compounds, Ovarian Neoplasms, Paclitaxel, Polyethylene Glycols, Self Report, Topotecan, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo determine the effects of bevacizumab on patient-reported outcomes (PROs; secondary end point) in the AURELIA trial.Patients and methodsPatients with platinum-resistant ovarian cancer were randomly assigned to chemotherapy alone (CT) or with bevacizumab (BEV-CT). PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module 28 (EORTC QLQ-OV28) and Functional Assessment of Cancer Therapy-Ovarian Cancer symptom index (FOSI) at baseline and every two or three cycles (8/9 weeks) until disease progression. The primary PRO hypothesis was that more patients receiving BEV-CT than CT would achieve at least a 15% (≥ 15-point) absolute improvement on the QLQ-OV28 abdominal/GI symptom subscale (items 31-36) at week 8/9. Patients with missing week 8/9 questionnaires were included as unimproved. Questionnaires from all assessments until disease progression were analyzed using mixed-model repeated-measures (MMRM) analysis. Sensitivity analyses were used to determine the effects of differing assumptions and methods for missing data.ResultsBaseline questionnaires were available from 89% of 361 randomly assigned patients. More BEV-CT than CT patients achieved a ≥ 15% improvement in abdominal/GI symptoms at week 8/9 (primary PRO end point, 21.9% v 9.3%; difference, 12.7%; 95% CI, 4.4 to 20.9; P = .002). MMRM analysis covering all time points also favored BEV-CT (difference, 6.4 points; 95% CI, 1.3 to 11.6; P = .015). More BEV-CT than CT patients achieved ≥ 15% improvement in FOSI at week 8/9 (12.2% v 3.1%; difference, 9.0%; 95% CI, 2.9% to 15.2%; P = .003). Sensitivity analyses gave similar results and conclusions.ConclusionBevacizumab increased the proportion of patients achieving a 15% improvement in patient-reported abdominal/GI symptoms during chemotherapy for platinum-resistant ovarian cancer.

Published
2014

35. Patients' perception of the benefits of palliative systemic therapy for advanced cancer.

Author

Subramaniam, Shalini, Adams, Diana H., Tognela, Annette, Roncolato, Felicia, Yip, Po Y., Lim, Stephanie H.‐S., Roohullah, Aflah, Stockler, Martin R., and Kiely, Belinda

Subjects
TUMOR treatment, CROSS-sectional method, SCALE analysis (Psychology), PALLIATIVE treatment, AUSTRALIANS, LIFE expectancy, QUESTIONNAIRES, VISUAL analog scale, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, QUALITY of life, TUMORS, ONCOLOGISTS, COMPARATIVE studies, DATA analysis software, PATIENTS' attitudes
Abstract

Background: Patients with advanced cancer who misunderstand their prognosis and chance of cure tend to overestimate the likely benefits of palliative systemic therapy. Aim: To determine patient perceptions of palliative systemic therapy benefits in advanced cancer. Methods: We surveyed 104 outpatients with advanced cancer receiving systemic anticancer therapy and their treating oncologists. Patients recorded their understanding of treatment impact on chance of cure and symptoms. Life expectancy was estimated by patients and oncologists. A visual analogue scale (0–10) was used to record how patients and oncologists valued quality of life (QOL) and length of life (LOL) (<4 QOL most important; 4–7 QOL and LOL equal; >7 LOL most important). Patient‐oncologist discordance was defined as a ≥4‐point difference. Results: The main reasons patients selected for receiving treatment were to live longer (54%) and cure their cancer (36%). Most patients reported treatment was very/somewhat likely to prolong life (84%) and improve symptoms (76%), whereas 20% reported treatment was very/somewhat likely to cure their cancer. 42% of patients selected a timeframe for life expectancy (choice of four timeframes between <1 year and ≥5 years); of these, 62% selected a longer timeframe than their oncologist. When making treatment decisions, 71% of patients (52% of oncologists) valued QOL and LOL equally. Patient‐oncologist discordance was 21%, mostly because of oncologists valuing QOL more than their patients (70%). Conclusion: At least 20% of patients receiving systemic therapy for advanced cancer reported an expectation of cure. Most patients and oncologists value QOL and LOL equally when making treatment decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Accuracy of oncologists’ estimates of expected survival time in advanced cancer

Author

Nahm, Sharon H, primary, Martin, Andrew J, additional, Clayton, Josephine M, additional, Grimison, Peter, additional, Moth, Erin B, additional, Pavlakis, Nick, additional, Sjoquist, Katrin, additional, Smith-Uffen, Megan E S, additional, Tognela, Annette, additional, Vasista, Anuradha, additional, Stockler, Martin R, additional, and Kiely, Belinda E, additional

Published
2023
Full Text
View/download PDF

38. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations

Author

Conduit, Ciara, primary, Lewin, Jeremy, additional, Weickhardt, Andrew, additional, Lynam, James, additional, Wong, Shirley, additional, Grimison, Peter, additional, Sengupta, Shomik, additional, Pranavan, Ganes, additional, Parnis, Francis, additional, Bastick, Patricia, additional, Campbell, David, additional, Hansen, Aaron R., additional, Leonard, Matt, additional, McJannett, Margaret, additional, Stockler, Martin R., additional, Gibbs, Peter, additional, Toner, Guy, additional, Davis, Ian D., additional, Tran, Ben, additional, and Kuchel, Anna, additional

Published
2023
Full Text
View/download PDF

39. An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals

Author

Yabroff, K Robin, primary, Boehm, Amanda L, additional, Nogueira, Leticia M, additional, Sherman, Mark, additional, Bradley, Cathy J, additional, Shih, Ya-Chen Tina, additional, Keating, Nancy L, additional, Gomez, Scarlett L, additional, Banegas, Matthew P, additional, Ambs, Stefan, additional, Hershman, Dawn L, additional, Yu, James B, additional, Riaz, Nadeem, additional, Stockler, Martin R, additional, Chen, Ronald C, additional, and Franco, Eduardo L, additional

Published
2023
Full Text
View/download PDF

40. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Author

GCIG Symptom Benefit group, King, Madeleine T., Stockler, Martin R., O'Connell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., and Friedlander, Michael L.

Published
2018

42. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Author

Roncolato, Felicia T., Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A., Kaminsky, Marie Christine, Stockler, Martin R., King, Madeleine T., and Friedlander, Michael

Published
2018
Full Text
View/download PDF

44. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

Author

Lindemann, Kristina, Beale, Philip J., Rossi, Emma, Goh, Jeff C., Vaughan, Michelle M., Tenney, Meaghan E., Martyn, Julie K., Sommeijer, Dirkje, Iglesias, Jose L., Kremmidiotis, Gabriel, Simpson, Jeremy, Doolin, Elizabeth, Lavranos, Tina C., Leske, Annabell, Veillard, Anneso S., Espinoza, David, Stockler, Martin R., Rischin, Danny, and For ANZGOG and HCRN Collaborative Groups

Published
2019
Full Text
View/download PDF

48. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).

Author

Mak, Blossom, Tran, Ben, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A, Wheater, Matthew, Walpole, Euan Thomas, Feldman, Darren R., Dunwoodie, Elaine, Lawrence, Nicola Jane, Birtle, Alison Jane, Wyld, David, Stevanovic, Amanda Gwendolyn, Balagtas, Jay Michael S., Stockler, Martin R., and Davis, Ian D.

Published
2024
Full Text
View/download PDF

49. Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Author

Niazi, Tamim, Nguyen, Paul L., Williams, Scott, Stockler, Martin R., Martin, Andrew James, Horvath, Lisa, Thomas, Hayley, Zebic, Danka Sinikovic, Roncolato, Felicia, Lim, Tee, Jose, Chakiath, Martin, Jarad, Chung, Hans T., Ebacher, Annie, Morgan, Scott C., Hughes, Simon, McBride, Sean Matthew, Kelly, Paul J., Davis, Ian D., and Sweeney, Christopher

Published
2024
Full Text
View/download PDF

50. Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).

Author

Davis, Ian D., Martin, Andrew James, Zielinski, Robert Richard, Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen, Reaume, M. Neil, Pook, David William, Parnis, Francis, North, Scott A., Marx, Gavin M., McCaffrey, John, McDermott, Raymond S., Inderjeeth, Andrisha Jade, Horvath, Lisa, Frydenberg, Mark, Chowdhury, Simon, Chi, Kim N., Stockler, Martin R., and Sweeney, Christopher

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results